New York State Common Retirement Fund increased its holdings in shares of BioLife Solutions, Inc. (NASDAQ:BLFS - Free Report) by 4.3% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 260,315 shares of the medical equipment provider's stock after acquiring an additional 10,836 shares during the quarter. New York State Common Retirement Fund owned about 0.56% of BioLife Solutions worth $6,758,000 at the end of the most recent reporting period.
Several other large investors also recently bought and sold shares of the business. Mark Sheptoff Financial Planning LLC acquired a new position in shares of BioLife Solutions during the 3rd quarter worth approximately $28,000. Quest Partners LLC acquired a new position in BioLife Solutions during the third quarter worth $57,000. Summit Global Investments purchased a new stake in BioLife Solutions in the 3rd quarter valued at $228,000. Intech Investment Management LLC acquired a new stake in shares of BioLife Solutions in the 3rd quarter worth $255,000. Finally, Stifel Financial Corp raised its holdings in shares of BioLife Solutions by 5.4% during the 3rd quarter. Stifel Financial Corp now owns 12,988 shares of the medical equipment provider's stock worth $325,000 after acquiring an additional 670 shares during the period. Hedge funds and other institutional investors own 93.24% of the company's stock.
Wall Street Analysts Forecast Growth
BLFS has been the subject of a number of analyst reports. Craig Hallum upped their price objective on shares of BioLife Solutions from $30.00 to $32.00 and gave the company a "buy" rating in a report on Wednesday, November 13th. HC Wainwright dropped their price target on shares of BioLife Solutions from $29.00 to $27.00 and set a "buy" rating for the company in a research note on Monday, November 18th. KeyCorp lifted their price target on shares of BioLife Solutions from $30.00 to $33.00 and gave the company an "overweight" rating in a research report on Friday, December 13th. Benchmark reiterated a "buy" rating and issued a $30.00 price objective on shares of BioLife Solutions in a research report on Thursday, December 19th. Finally, Northland Securities lifted their target price on BioLife Solutions from $28.00 to $31.00 and gave the company an "outperform" rating in a research report on Wednesday, January 8th. One research analyst has rated the stock with a sell rating and seven have issued a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $29.43.
Read Our Latest Report on BioLife Solutions
BioLife Solutions Trading Up 1.8 %
NASDAQ BLFS traded up $0.42 on Friday, reaching $24.00. The stock had a trading volume of 425,089 shares, compared to its average volume of 256,297. The company has a quick ratio of 1.78, a current ratio of 2.78 and a debt-to-equity ratio of 0.03. The stock has a fifty day moving average price of $26.74 and a two-hundred day moving average price of $25.50. BioLife Solutions, Inc. has a 12-month low of $14.50 and a 12-month high of $29.55. The firm has a market capitalization of $1.11 billion, a price-to-earnings ratio of -22.64 and a beta of 1.91.
Insider Activity
In related news, CFO Troy Wichterman sold 987 shares of the firm's stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $27.02, for a total transaction of $26,668.74. Following the completion of the transaction, the chief financial officer now directly owns 121,779 shares in the company, valued at $3,290,468.58. This trade represents a 0.80 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Aby J. Mathew sold 7,604 shares of the business's stock in a transaction dated Monday, December 16th. The stock was sold at an average price of $27.33, for a total transaction of $207,817.32. Following the sale, the executive vice president now owns 276,315 shares in the company, valued at $7,551,688.95. This trade represents a 2.68 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 10,009 shares of company stock valued at $272,594. 2.20% of the stock is currently owned by corporate insiders.
BioLife Solutions Company Profile
(
Free Report)
BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.
Read More
Before you consider BioLife Solutions, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioLife Solutions wasn't on the list.
While BioLife Solutions currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
